WeChat Mini Program
Old Version Features

A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients with Advanced Solid Tumors.

Elena Garralda,Alison M. Schram,Philippe L. Bedard,Gary K. Schwartz,Eunice Yuen,Samuel C. McNeely,Silvia Ribeiro,Jason Cunningham,Yi Wang,Arantxa Urunuela,Xiaojian Xu,Patricia LoRusso

ONCOLOGIST（2024）

Cited 6|Views19
Key words
solid tumors,cyclin-dependent kinase 7,cyclin-dependent kinase inhibitor,phase I
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined